ERBB2 and neoplasm: The diagnostics radioconjugate 89Zr-DOTA-pertuzumab tested in (Kang et al. 2022) exhibited elevated uptake in HER2 + tumour (JIMT-1 cell line) of about 18% ID/g after 7 days p.i., and minimal accumulation in HER2- tumour (MDA-MB-231) with less than 8% ID/g.